ALX Oncology Pairs Lead Asset with Keytruda in HNSCC Study

ALX Oncology will partner with pharma giant Merck to evaluate a combination of its CD47 inhibitor with Keytruda as a potential treatment for patients with Head & Neck Squamous Cell Carcinoma (HNSCC).